Quest Diagnostics

Q3 FY2026 EarningsQ3 FY26 beat consensus across all key financial metrics, with revenue of $3.10B vs. $3.05B expected and normalized EPS of $2.78 exceeding the $2.57 GAAP consensus. Growth was driven by a 14.5% surge in DIS volume, fueled by new strategic relationships with Corewell Health and Fresenius Medical Care. While revenue per requisition fell 4.2% due to business mix, organic volume growth of 14.4% and disciplined cost management via the Invigorate program bolstered operating margins to 15.5%.